NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Given Average Recommendation of “Buy” by Brokerages

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) has been assigned an average recommendation of “Buy” from the six analysts that are currently covering the stock, MarketBeat reports. One research analyst has rated the stock with a hold recommendation, four have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $34.50.

A number of equities analysts have recently issued reports on NRXP shares. Zacks Research upgraded shares of NRx Pharmaceuticals to a “hold” rating in a report on Wednesday, September 10th. BTIG Research restated a “buy” rating on shares of NRx Pharmaceuticals in a report on Monday, August 25th. D. Boral Capital restated a “buy” rating and set a $34.00 target price on shares of NRx Pharmaceuticals in a report on Thursday. Finally, HC Wainwright started coverage on shares of NRx Pharmaceuticals in a report on Monday, September 8th. They set a “buy” rating and a $40.00 target price for the company.

Hedge Funds Weigh In On NRx Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the business. Geode Capital Management LLC boosted its stake in shares of NRx Pharmaceuticals by 27.9% during the 2nd quarter. Geode Capital Management LLC now owns 172,255 shares of the company’s stock worth $562,000 after purchasing an additional 37,598 shares during the last quarter. Anson Funds Management LP boosted its stake in shares of NRx Pharmaceuticals by 535.1% during the 1st quarter. Anson Funds Management LP now owns 1,179,061 shares of the company’s stock worth $2,417,000 after purchasing an additional 993,401 shares during the last quarter. Squarepoint Ops LLC acquired a new stake in shares of NRx Pharmaceuticals during the 4th quarter worth about $56,000. Finally, Millennium Management LLC acquired a new stake in shares of NRx Pharmaceuticals during the 4th quarter worth about $61,000. 4.27% of the stock is currently owned by hedge funds and other institutional investors.

NRx Pharmaceuticals Trading Up 1.4%

Shares of NASDAQ:NRXP opened at $2.95 on Wednesday. The company’s 50 day moving average is $2.74 and its two-hundred day moving average is $2.62. NRx Pharmaceuticals has a 52 week low of $1.10 and a 52 week high of $6.01. The company has a market cap of $58.44 million, a PE ratio of -1.32 and a beta of 1.63.

NRx Pharmaceuticals (NASDAQ:NRXP) last issued its quarterly earnings results on Monday, August 18th. The company reported ($0.98) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.67). As a group, equities research analysts expect that NRx Pharmaceuticals will post -1.75 EPS for the current year.

NRx Pharmaceuticals Company Profile

NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.